MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-10-2025
uniQure N.V. Accounts Payables 2011-2026 | QURE
Accounts payable — are the obligations of an organization to other legal entities or individuals that arise in cases when the company has acquired goods or services on deferred payment terms, has not paid taxes and fees, has wage arrears to employees, or has received loans and other liabilities. Accounts payable arise when an organization has already received some benefit but has not yet paid for it.Main types of accounts payable
| Type of liability | Example |
|---|---|
| To suppliers and contractors | Goods received but not yet paid for |
| Taxes and fees | VAT, income tax, etc., not paid on time |
| Salaries | Employee wages not paid |
| To budgets | Insurance contributions to funds not paid |
| To founders | Founders provided borrowed funds |
| To banks | Overdue loan payments |
| Other | Fines, penalties, forfeits, customer prepayments, etc. |
Impact on the company's financial performance
- Liquidity and solvency
Accounts payable are part of short-term liabilities, so they affect liquidity ratios - Financial stability
The higher the share of borrowed funds (including accounts payable), the lower the company's level of independence - Capital turnover
Moderate accounts payable can positively affect working capital by allowing the company to use “free” financing from suppliers (payment deferrals) - Risks and reputation
Large and especially overdue accounts payable may indicate financial difficulties. This can deter investors, partners, and lenders, and at a critical level of debt and lack of resources to repay it, bankruptcy proceedings may be initiated
Annual Accounts Payables uniQure N.V.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 7.23 M | 6.59 M | 11 M | 2.5 M | 3.77 M | 5.68 M | 3.79 M | 2.91 M | 5.52 M | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 11 M | 2.5 M | 5.44 M |
Quarterly Accounts Payables uniQure N.V.
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6.23 M | 5.54 M | 5.27 M | 7.23 M | 5.44 M | 4.41 M | 5.23 M | 6.59 M | 5.58 M | 9.37 M | 8.88 M | 11 M | 7.57 M | 10 M | 9.92 M | 2.5 M | 5.37 M | 16.8 M | 5.75 M | 3.77 M | 3.77 M | 3.77 M | 3.77 M | 5.68 M | 5.68 M | 5.68 M | 5.68 M | 3.79 M | 3.79 M | 3.79 M | 3.79 M | 2.91 M | 2.91 M | 2.91 M | 2.91 M | 5.52 M | 5.52 M | 5.52 M | 5.52 M | 4.06 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 16.8 M | 2.5 M | 5.74 M |
Accounts Payables of other stocks in the Biotechnology industry
| Issuer | Accounts Payables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Alector
ALEC
|
1.69 M | $ 2.19 | -9.77 % | $ 226 M |  USA |
 |
Acer Therapeutics
ACER
|
3.81 M | - | 2.71 % | $ 14 M | USA |
 |
I-Mab
IMAB
|
570 M | - | - | $ 866 M |  China |
 |
Cabaletta Bio
CABA
|
4.55 M | $ 3.34 | 0.45 % | $ 3.9 M | USA |
 |
AgeX Therapeutics
AGE
|
1.41 M | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
677 K | - | - | $ 1.01 B | USA |
 |
Codexis
CDXS
|
2.84 M | $ 1.02 | 1.49 % | $ 74.9 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
2.91 M | - | - | $ 26.5 M | USA |
 |
Cerus Corporation
CERS
|
21.7 M | $ 2.6 | 1.37 % | $ 480 M | USA |
 |
ARCA biopharma
ABIO
|
3.46 M | - | 1052.0 % | $ 415 M | USA |
 |
Acorda Therapeutics
ACOR
|
13.4 M | - | -24.86 % | $ 820 K | USA |
 |
Acasti Pharma
ACST
|
601 K | - | 4.01 % | $ 150 M |  Canada |
 |
CNS Pharmaceuticals
CNSP
|
1.98 M | $ 3.23 | 2.22 % | $ 1.23 M | USA |
 |
Adverum Biotechnologies
ADVM
|
1.61 M | - | - | $ 86.2 M | USA |
 |
Collegium Pharmaceutical
COLL
|
10.7 M | $ 41.75 | 0.19 % | $ 1.32 B | USA |
 |
Akero Therapeutics
AKRO
|
9.03 M | - | - | $ 3.67 B | USA |
 |
Akouos
AKUS
|
1.28 M | - | 0.23 % | $ 488 M | USA |
 |
Albireo Pharma
ALBO
|
6.52 M | - | -0.23 % | $ 916 M | USA |
 |
Corcept Therapeutics Incorporated
CORT
|
40.4 M | $ 36.14 | 1.23 % | $ 3.75 B | USA |
 |
Allena Pharmaceuticals
ALNA
|
1.03 M | - | 3.16 % | $ 1.9 M | USA |
 |
Amarin Corporation plc
AMRN
|
52.8 M | $ 13.98 | 1.27 % | $ 5.7 B |  Irlanda |
 |
Aileron Therapeutics
ALRN
|
911 K | - | 10.36 % | $ 9.8 M | USA |
 |
AlloVir
ALVR
|
247 K | - | 4.14 % | $ 49.1 M | USA |
 |
Catalyst Pharmaceuticals
CPRX
|
11.2 M | $ 23.77 | 2.99 % | $ 2.91 B | USA |
 |
Alpine Immune Sciences
ALPN
|
4.29 M | - | - | $ 2.17 B | USA |
 |
Corbus Pharmaceuticals Holdings
CRBP
|
3.18 M | $ 8.41 | -1.87 % | $ 36.4 M | USA |
 |
Cardiff Oncology
CRDF
|
8.09 M | $ 1.94 | 0.01 % | $ 130 M | USA |
 |
Curis
CRIS
|
3.02 M | $ 1.1 | -3.51 % | $ 6.94 M | USA |
 |
CorMedix
CRMD
|
4.28 M | $ 7.16 | 0.42 % | $ 364 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
750 K | - | -11.43 % | $ 502 K | USA |
 |
Applied Molecular Transport
AMTI
|
1.58 M | - | - | $ 10.1 M | USA |
|
Champions Oncology
CSBR
|
4.25 M | $ 6.14 | 3.89 % | $ 83.9 M | USA |
 |
Aravive
ARAV
|
8.76 M | - | -13.39 % | $ 1.45 M | USA |
 |
Aptose Biosciences
APTO
|
1.26 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Aptinyx
APTX
|
724 K | - | -39.0 % | $ 4.57 M | USA |
 |
Citius Pharmaceuticals
CTXR
|
4.93 M | $ 0.72 | -2.34 % | $ 4.84 M | USA |
 |
Athira Pharma
ATHA
|
319 K | - | - | $ 269 M | USA |
 |
Aridis Pharmaceuticals
ARDS
|
2.31 M | - | 17.91 % | $ 11.1 M | USA |
 |
Altimmune
ALT
|
211 K | $ 4.21 | -2.32 % | $ 299 M | USA |
 |
CEL-SCI Corporation
CVM
|
1.45 M | $ 3.88 | -8.92 % | $ 247 M | USA |